MRNS Stock Recent News

Interim results from a late-stage study show that Marinus' (MRNS) ganaxolone failed to meet the pre-specified stopping criteria in patients with refractory status epilepticus.

The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 biotech stocks. Imagine you acquired shares of a popular, richly priced enterprise, only for the underlying security to suffer due to a poor clinical result.

Marinus Pharmaceuticals (NASDAQ: MRNS ) stock is taking a beating on Monday after the pharmaceutical company announced results from a Phase 3 clinical trial. It's bad news for MRNS stockholders today as the Phase 3 trail of intravenous ganaxolone as a treatment for refractory status epilepticus (RSE) failed to meet expectations.

Start Time: 16:30 End Time: 17:36 March 1, 0000 ET Q4 2023 Earnings Conference Call March 05, 2024, 16:30 PM ET

Marinus Pharmaceuticals (MRNS) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.76 per share a year ago.

Here, we discuss some reasons why investing in Marinus Pharmaceuticals' (MRNS) stock may turn out to be a prudent move.

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS ) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET Company Participants Sonya Weigle - SVP, IR Scott Braunstein - CEO, President & Chairman Christina Shafer - Chief Commercial Officer Joseph Hulihan - Chief Medical Officer Steven Pfanstiel - COO, CFO & Treasurer Thomas Lyons - Chief Business Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Joseph Thome - TD Cowen Joon Lee - Truist Securities Andrew Tsai - Jefferies Marc Goodman - Leerink Partners Charles Duncan - Cantor Fitzgerald & Co. Douglas Tsao - H.C. Wainwright & Co. Operator Greetings and welcome to the Marinus Pharmaceuticals' Third Quarter 2023 Financial Results and Business Update Call.

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the third quarter ended September 30, 2023 on November 7, 2023. The Company will host a conference call at 8:30 a.m. Eastern Time on November 7, 2023. Participants may access the conference call via webcast on the Investors and Media page of Marinus'.

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that Scott Braunstein, M.D., Chairman and Chief Executive Officer, will be participating in a fireside chat at the 2023 Cantor Global Healthcare Conference. The fireside chat will take place on Thursday, September 28 beginning at 10:55 a.m. Eastern Time. A link to the event can be accessed on the.

Marinus' (MRNS) shares rise as it provides revenue and cash guidance for third-quarter 2023. The company also updates on the progress of its pipeline candidates targeting major central nervous system disorders.